Italia markets closed

Immutep Limited (IMM.XA)

Cboe AU - Cboe AU Prezzo in tempo reale. Valuta in AUD.
Aggiungi a watchlist
0,4350+0,0150 (+3,57%)
Alla chiusura: 03:59PM AEST
Schermo intero
Chiusura precedente0,4200
Aperto0,4250
Denaro0,4300 x N/D
Lettera0,4450 x N/D
Min-Max giorno0,4250 - 0,4400
Intervallo di 52 settimane0,2250 - 0,4500
Volume700.759
Media Volume1.388.419
CapitalizzazioneN/D
Beta (5 anni mensile)1,83
Rapporto PE (ttm)N/D
EPS (ttm)-0,0350
Prossima data utili28 lug 2024 - 01 ago 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1AN/D
  • GlobeNewswire

    Immutep Announces Publication of Abstracts at ESMO Congress 2023

    Media Release New updated data from TACTI-002, including more mature Overall Survival data, will be presented during the Mini Oral session on Saturday, October 21st, at 9:05 CESTImmutep to host webcast to discuss ESMO 2023 clinical data on Monday, October 23rd, at 8AM AEDT (Sunday, October 22nd, at 5PM ET) SYDNEY, AUSTRALIA, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immuno

  • GlobeNewswire

    Immutep Announces Abstract Accepted for Presentation at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting

    Media Release SYDNEY, AUSTRALIA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a clinical-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease, today announces an abstract has been accepted for poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting 2023, taking place in San Diego, California and virtually from 1 to 5 November 2023. Presentation DetailsTitle: Biomarke

  • GlobeNewswire

    Commercial Manufacturing of Eftilagimod Alpha at 2000L Scale Granted Authorization for Clinical Trial Use

    Comparability of Drug Substance and Drug Product manufactured at 2,000L scale achievedMedia Release SYDNEY, AUSTRALIA, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune disease, today announces the regulatory authorization of eftilagimod alpha (“efti”) manufactured at commercial 2,000L scale for use in clinical trials across multiple Euro